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Abstract
Caffeine administration is an important part of the therapeutic treatment of bronchopulmonary dysplasia (BPD) in preterm
infants. However, caffeine mediated effects on airway remodelling are still undefined. The TGF-b/Smad signalling pathway is
one of the key pathways involved in airway remodelling. Connective tissue growth factor (CTGF), a downstream mediator of
TGF-b, and transgelin, a binding and stabilising protein of the cytoskeleton, are both regulated by TGF-b1 and play an
important role in airway remodelling. Both have also been implicated in the pathogenesis of BPD. The aim of the present
study was to clarify whether caffeine, an unspecific phosphodiesterase (PDE) inhibitor, and rolipram, a prototypical PDE-4
selective inhibitor, were both able to affect TGF-b1-induced Smad signalling and CTGF/transgelin expression in lung
epithelial cells. Furthermore, the effect of transgelin knock-down on Smad signalling was studied. The pharmacological
effect of caffeine and rolipram on Smad signalling was investigated by means of a luciferase assay via transfection of a TGF-
b1-inducible reporter plasmid in A549 cells. The regulation of CTGF and transgelin expression by caffeine and rolipram were
studied by promoter analysis, real-time PCR and Western blot. Endogenous transgelin expression was down-regulated by
lentiviral transduction mediating transgelin-specific shRNA expression. The addition of caffeine and rolipram inhibited TGF-
b1 induced reporter gene activity in a concentration-related manner. They also antagonized the TGF-b1 induced up-
regulation of CTGF and transgelin on the promoter-, the mRNA-, and the protein-level. Functional analysis showed that
transgelin silencing reduced TGF-b1 induced Smad-signalling and CTGF induction in lung epithelial cells. The present study
highlights possible new molecular mechanisms of caffeine and rolipram including an inhibition of Smad signalling and of
TGF-b1 regulated genes involved in airway remodelling. An understanding of these mechanisms might help to explain the
protective effects of caffeine in prevention of BPD and suggests rolipram to be a potent replacement for caffeine.
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Introduction
Bronchopulmonary dysplasia (BPD) today is still one major
challenge for preterm infants [1,2]. BPD is characterized by a
disruption of normal lung alveolarization and vascularisation,
leading to fewer but larger alveoli and a simplification of the
vascular structures [3]. BPD is clinically defined by requirement of
supplemental oxygen at 36 weeks gestation [2]. The disease can be
complicated by development of pulmonary hypertension (PH) [1].
The etiology of BPD is multifactorial, including extreme lung
immaturity combined with lung injury implicating inflammatory
and remodelling responses induced by mechanical ventilation,
oxygen stress, and/or infection [3].
The TGF-b/Smad signalling pathway is one of the key
pathways involved in lung development, airway inflammation,
airway remodelling, and lung fibrosis [4,5]. All of these processes
contribute to the development of BPD [3,6]. In BPD, increased
expression of TGF-b and activation of Smad signalling could be
described [7–11].
CTGF and transgelin, both downstream mediators of TGF-b
and both regulated in a TGF-b/Smad3 dependent fashion
[12,13], contribute to TGF-b dependent airway/vascular remod-
elling processing in BPD [9,11,14–16]. Like for CTGF [17], in
pulmonary fibrosis and pulmonary hypertension an increased
transgelin expression could also be described [18–20]. While a
direct influence of CTGF on Smad signalling was shown [21], an
impairment of Smad signalling by transgelin is only hypothesized
[22].
The incidence of bronchopulmonary dysplasia (BPD) can be
reduced by the application of caffeine [23]. The molecular basis of
the protective actions of caffeine and its metabolites (paraxanthine,
theobromine, and theophylline) in airway remodelling processes of
the neonatal immature lung is not well defined. In addition, the
different molecular actions mediated by caffeine are highly dose
dependent [24]. At high plasma concentrations, caffeine, like
theophylline, acts as a non-selective phosphodiesterase (PDE)
inhibitor, thereby leading to higher levels of the intracellular
second messenger cyclic adenosine monophosphate (cAMP) [24].
cAMP was one of the first identified second messengers
transmitting signals via G-protein-coupled receptors and protein
kinase A (PKA) from the cell surface to the nucleus [25]. cAMP
suppresses the activation of inflammatory cells like mast cells,
eosinophils, neutrophils, monocytes, and lymphocytes. It also
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mediates a relaxation of airway smooth muscle through activation
of PKA and PKB, thereby leading to bronchodilation [25]. The
role of cAMP in airway remodelling processes, however, is less well
defined.
Currently, there are at least eleven genetically different PDE iso-
enzymes known [26]. Among the PDE iso-enzymes, PDE-4 is
highly specific for cAMP and is its major metabolizing enzyme in
the airways [26]. In addition, PDE-4 is also the dominant iso-
enzyme in inflammatory cells, which underlines that specific PDE-
4 inhibitors like rolipram, beside their actions as bronchodilators,
would be useful as an anti-inflammatory treatment in different
inflammatory pulmonary diseases. These might include asthma,
chronic obstructive pulmonary disease (COPD), or BPD [24,27–
31]. The potential benefit of an unselective PDE inhibitor like
caffeine or theophylline and a more specific PDE4-inhibitor like
rolipram in diseases associated with abnormal tissue remodelling
like BPD is insufficiently characterized.
In this context, the current study was designed to address the
question if there exist possible effects of caffeine and rolipram on
the Smad signalling pathway and on expression levels of TGF-b
family members (CTGF and transgelin) involved in airway
remodelling processes in lung epithelial cells.
Methods
Reagents
Recombinant TGF-b1 was obtained from R&D Systems
(Abingdon, UK). Caffeine, rolipram, and dibutyryl-cAMP (db-
cAMP) were purchased from Sigma-Aldrich (St. Louis, CA).
Cells
A549 cells, a human lung carcinoma cell line with character-
istics of human alveolar basal epithelial cells, were purchased from
ATCC (LGC Standards, Teddington, UK) [32]. A549 cells were
cultured in RPMI 1694 and DMEM (Gibco, Life Technologies,
Carlsbad, CA) with additional 5% fetal bovine serum, 100 U/mL
penicillin, and 100 mg/mL streptomycin (Gibco). Experiments
with TGF-b1 were performed in serum-free medium. Incubation
was carried out at 37uC in a humidified atmosphere with 5% CO2.
Cell viability assay
A549 cell viability after exposure to TGF-b1 (10 ng/ml),
caffeine (10 mM), rolipram (100 mM), and db-cAMP (10 mM)
was evaluated after 1–3 days using methylthiazolyldiphenyl-
tetrazolium bromide (MTT). Cells were seeded in six well plates
(Greiner) and treated as described. After washing with Dulbecco’s
Phosphate Buffered Saline (DPBS; Sigma-Aldrich), 1 mL DPBS
containing 1.2 mM MTT was applied to the cells and the plates
were incubated at 37uC for 30 min. The MTT-medium was then
removed, 500 mL isopropanol was added to the wells, and plates
were gently rocked for 5 min at RT to dissolve purple formazan
from vital cells. Optical density was measured in triplicates in 96
well plates (Greiner) with an MR 5000 microplate reader
(Dynatech, Santa Monica, CA) at 550 nm. Untreated cells were
considered 100% vital and used as reference.
Transfection and promoter assays
The human transgelin (TAGLN) promoter sequence (GenBank
ID EF153019.1) was cloned into the pGL3 Basic vector (Promega,
Fitchburg, WI) between BglII and HindIII sites by amplification
from A549 genomic DNA using primers BglIITAGLNprmtFwd
59-CACCAGATCTGTCCAGGGATCCCACTGTTAGTC-39
and HindIIITAGLNprmtRev 59-CCTAAAGCT-
TAGGCTTCCTCAGGGCTCGC-39, respectively. Cloning of
the (CAGA)12-and p3TP-luciferase plasmid were described before
[33,34]. The CAGA elements were originally found in the
promoter region of plasminogen activator inhibitor-1 and are
known to be activated after binding of the Smad3/4 complexes
and after TGF-b1 binding to the TGF-b receptor [33]. (CAGA)12-
luc (2 mg), p3TP-luc (2 mg) or the transgelin-promotor vector
(2 mg), and Renilla luciferase control reporter vector (phRL-TK;
5 ng) were transfected into A549 cells, seeded in 6-well plates,
using 6 mg of linear polyethylenimine MW 25,000 (Polysciences
Inc., Warrington, PA). Transfection medium (Optimem, Invitro-
gen) was changed to Optimem with additional 0.2% fetal bovine
serum after 2 hours. Twenty-four hours after transfection, cells
were treated with indicated molecules. Then 16 hours later,
luciferase activity was measured by the dual luciferase assay system
(Promega Biotech Inc., Madison, Wis) according to the manufac-
turer’s instruction using a Berthold MiniLumat LB 9506
luminometer (Bad Wildbach, Germany). Firefly luciferase activity
was normalized to the activity of Renilla luciferase under control
of thymidine kinase promoter of phRL-TK. Results are given as
relative increase compared to controls. All values were obtained
from experiments carried out in triplicates and repeated at least
three times. The error bars indicated standard error of the mean
(SEM).
RNA extraction and RT-PCR
For RNA extraction, 36105 A549 cells were seeded on six well
plates (Greiner, Frickenhausen, Germany) and grown at 37uC.
Cells were washed with DPBS and treated as indicated. After the
appropriate time, cells were washed again and total RNA was
isolated using NucleoSpin RNA II Kit (Macherey-Nagel, Dueren,
Germany) according to the manufacturer’s protocol. Total RNA
was eluted in 60 mL nuclease-free H2O and stored at -80uC until
reverse transcription. For RT-PCR, 1 mg of total RNA was reverse
transcribed using High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Life Technologies, Carlsbad, CA) according
to the manufacturer’s instructions. Upon analysis, first strand
cDNA was stored at 220uC.
Quantitative real time RT-PCR (qPCR)
For detection of human CTGF, transgelin, and GAPDH
mRNA, cDNA was analyzed using 12.5 mL iQTM SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA), 0.5 mL deionized
H2O, and 10 pmol of each forward and reverse primer,
respectively. Primers for CTGF, transgelin, and GAPDH mRNA
were hCTGFfwd 59-ACCCAACTATGATTAGAGCC-39,
hCTGFrev 59-TTGCCCTTCTTAATGTTCTC-39,
hTAGLNfwd 59-CGAGAAGAAGTATGACGAGG-39,
hTAGLNrev 59-CTTGCTCAGAATCACGCC-39,
hGAPDHfwd 59-CAAAGTTGTCATGGATGACC-39, and
hGAPDHrev 59-CCATGGAGAAGGCTGGGG-39, respectively,
and were designed based on genomic and mRNA sequences for
CTGF (accession numbers NG_016131 and NM_001901.2),
transgelin (accession numbers EF445034.1 and
NM_001001522.1), and GAPDH (accession numbers
NG_007073.2 and NM_002046.5) using PerlPrimer software
version 1.1.20. Real-time PCRs were performed on an ABI Prism
7500 Sequence Detection System (TaqMan) as described [35].
Melt curve analyses were performed to verify single PCR products.
Results were normalized to GAPDH and mean fold changes were
calculated by the DDCT method [36].
Western blot analysis
A549 cells were rinsed with ice-cold tris-buffered saline (TBS)
and incubated in 100 ml lysis buffer consisting of Cell lysis buffer
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(Cell Signaling Technologies, MA), Complete Mini protease
inhibitor cocktail tablets and PhosStop phosphatase inhibitor
cocktail tablets (Roche, Germany), and 0.1 mM PMSF (Merck
KGaA, Germany) for 10 minutes on ice. The lysate was cleared by
centrifugation at 30,000 g for 10 min, and the supernatant was
used for Western immunoblotting analysis. Protein concentrations
were determined for each sample using the Bradford assay (Bio-
Rad, Richmond, CA). Equal amounts of cellular protein were
loaded and separated by SDS-PAGE on 10% to 12% Bis-Tris gels
and electrophoretically transferred to polyvinylidene difluoride or
nitrocellulose blotting membranes (Amersham Pharmacia Biotech,
Piscataway, NJ). Membranes were blocked in 5% BSA for 1 hour
at room temperature and successively incubated with primary
antibodies overnight at 4uC. Western blots were probed with
primary antibodies to CTGF (ab6992; Abcam, Cambridge, UK),
transgelin (sc-50446; Santa Cruz Biotechnology, Santa Cruz, CA),
Smad2/3-P (rabbit anti-Smad2/3-P was a gift from Dr. C.-H.
Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden))
and b-actin (926–42212; LI-COR Inc., Lincoln, NE), followed by
staining with corresponding IRDye secondary antibodies (LI-
COR Inc.) for 1 h at room temperature. Specific protein bands
were visualized using an Odyssey Infrared Imaging System (LI-
COR Inc.). Accumulated signals were quantifieded using Odyssey
Software v2.1 (LI-COR Inc.).
Transgelin Gene Silencing by Lentiviral Transduction
For expression of transgelin-specific shRNA, the lentiviral
system as described by Zinke et al. was used [37]. The transgelin
specific siRNA sequence 59-GGCTCTGTCACTGAGCAAT-39
and the inactive control siRNA (scrmbl) sequence 59-CCAGAGC-
TATCTCAGATAG-39, respectively, embeded in the cellular
human miR30 pre-micro-RNA backbone, were introduced into a
modified, shRNA-expressing F6GW vector using HpaI and XhoI
sites. F6GW was modified to contain a puromycin N-acetyl-
transferase sequence instead of those for EGFP using BamHI and
EcoRI sites. The correct sequence of all constructs was verified by
sequencing. Vesicular stomatitis virus envelope protein G (VSV-
G)-pseudotyped lentiviral particles were produced by transfection
of 293T cells with plasmids F6GW-shRNATAGLN or F6GW-
shRNAscrmbl, respectively, pMDLg, pRSV-Rev, and pMD.G as
described [37]. Sterile-filtered particles were further concentrated
using 100 kDa Amicon Ultra-15 filters (Merck Millipore, Billerica,
MA). After transduction with shRNA-expressing lentiviral vectors,
A549 cells were expanded in culture medium containing 2 mg/mL
puromycin. No differences on cell morphology and proliferation
were observed between transduced cells.
Data analysis
All results shown are representative of three separate experi-
ments. Results are given as means 6SEM. Data were analyzed by
the Mann-Whitney-Wilcoxon test. A p-value ,0.05 was consid-
ered significant. All statistical analyses were performed using the
statistical software GraphPad Prism 5.0.
Results
Effect of caffeine, rolipram, and db-cAMP on TGF-b1
induced Smad-signalling in lung epithelial cells
To investigate the possible effect of caffeine, rolipram, and the
membrane-permeable cAMP analog dibutyryl-cyclic AMP (db-
cAMP) on Smad-signalling in lung epithelial cells, a TGF-b1–
sensitive (CAGA)12-luciferase construct was transfected into lung
epithelial cells A549. As a positive control, TGF-b1 induced a
significant increase of reporter gene activity compared to
untreated lung epithelial cells A549 using the (CAGA)12-luciferase
construct (Figure 1A–C) (p,0.05). Caffeine (Figure 1A), rolipram
(Figure 1B), and db-cAMP (Figure 1C) inhibited the TGF-b1
induced reporter gene activity in a concentration-related manner.
Caffeine at 10 mM was able to antagonize the effect of TGF-b1 on
Smad activation completely (p,0.05) (Figure 1A). Rolipram, used
in a concentration of 100 mM, reduced TGF-b1 induced Smad
activity by 75613% (p,0.05) (Figure 1B) and db-cAMP at
10 mM reduced Smad activity by 80618% (p,0.05) (Figure 1C).
Taken together, these results showed that TGF-b1 is able to
activate the Smad signalling pathway in A549 cells. In turn, the
unspecific PDE inhibitor caffeine, the more specific PDE-4
inhibitor rolipram, and the cAMP analog db-cAMP were able to
inhibit the effect of TGF-b1 on Smad signalling activation in lung
epithelial cells.
Effect of caffeine and rolipram on TGF-b1 induced CTGF
expression in lung epithelial cells
As a next step, we wanted to study the effect of caffeine and
rolipram on expression of the TGF-b1 regulated gene CTGF in
lung epithelial cells. A549 cells were treated with TGF-b1 and
with or without caffeine or rolipram. CTGF mRNA and protein
expression was measured 12 or 24 hours later, respectively. TGF-
b1 alone increased CTGF mRNA levels 4.4-fold compared to
untreated cells (p,0.05) (Figure 2A+C). Caffeine and rolipram
alone had no significant effect on CTGF mRNA expression
(Figure 2A+C). TGF-b1-induced CTGF expression was reduced
to 5467% (p,0.05) by caffeine (Figure 2A) and completely by
rolipram (p,0.05) (Figure 2C). The inhibitory effect of caffeine
and rolipram on TGF-b1 mediated CTGF mRNA up-regulation
was confirmed on the protein level by immunoblotting (Figure 2B+
D).
These results demonstrated that TGF-b1 is able to enhance
CTGF expression in A549 cells, which was diminished by caffeine
and abolished by rolipram.
Regulation of transgelin by TGF-b1 and caffeine in lung
epithelial cells
Next we examined the effect of TGF-b1 and caffeine on
transgelin expression in A549 cells.
TGF-b1 significantly induced transgelin promoter activity in a
dose dependent manner (Figure 3A). The maximum increase of
luciferase activity was a 4.6-fold increase with 10 ng/ml TGF-b1
(p,0.05) (Figure 3A). At the transcriptional-level, TGF-b1 also
increased transgelin mRNA levels in a dose-dependent manner
(Figure 3B). A maximum increase of transgelin mRNA by TGF-b1
was observed at a concentration of 5 ng/ml (10.5-fold increase)
after 12 h (p,0.05). At the translation-level, TGF-b1 increased
transgelin protein expression in A549 cells in a dose-dependent
manner with a maximum increase using 10 ng/ml TGF-b1 after
24 h (Figure 3C). Caffeine was able to inhibit transgelin promoter
activity in a dose dependent manner (Figure 3D). At a
concentration of 10 mM, caffeine reduced transgelin promoter
activity by 7167% compared to untreated cells (p,0.05)
(Figure 3D). At the transcriptional- and translational-level we
found a dose- and time-dependent reduction of transgelin mRNA
by 8569% after 12 h (Figure 3E) and a maximal decrease of
protein expression after 72 h (Figure 3F) using 10 mM caffeine.
In summary, these data showed that TGF-b1 induced and
caffeine inhibited transgelin expression in lung epithelial cells.
Effect of Caffeine and Rolipram on Airway Remodelling
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Effect of caffeine and rolipram on TGF-b1 induced
transgelin expression in lung epithelial cells
Next, we studied the effect of caffeine and rolipram on TGF-b1
induced up-regulation of transgelin. To evaluate potential effects,
promoter-analysis, PCR, and immunoblotting was performed in
lung epithelial cells.
Figure 1. Caffeine, rolipram, and db-cAMP inhibit TGF-b1
induced Smad-signalling in lung epithelial cells. The TGF-b1–
sensitive (CAGA)12-luciferase reporter construct was transiently trans-
fected into A549 cells. Cells were then treated with TGF-b1 (10 ng/ml)
and/or different concentrations of caffeine (A), rolipram (B), or db-cAMP
(C). Firefly luciferase activity was normalized to the activity of Renilla
luciferase under control of the thymidine kinase promoter. Relative
luciferase activity compared to controls is shown. * p,0.05 compared
to control cells, # p,0.05 compared to TGF-b1 treated cells.
doi:10.1371/journal.pone.0097357.g001
Figure 2. Caffeine and rolipram inhibit TGF-b1 induced CTGF
expression in lung epithelial cells. A549 cells were incubated with
TGF-b1 (10 ng/ml) and with or without caffeine (10 mM) or rolipram
(50 mM). Real-time PCR of CTGF mRNA was performed after 12h (A+C)
and Western blot analysis after 24 h (B+D). Relative mRNA levels of
CTGF were calculated by normalizing signals to detected GAPDH
mRNA. Differences compared to untreated cells were calculated (A+C).
Means6SD of at least n = 3 independent experiments are shown. In B+
D representative immunoblots of at least three independent experi-
ments are shown. * p,0.05 compared to control cells, # p,0.05
compared to cells treated with TGF-b1.
doi:10.1371/journal.pone.0097357.g002
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For promoter analysis, A549 cells were transfected with a
luciferase-reporter construct containing the promoter of the
human transgelin gene and treated with TGF-b1 with or without
different concentrations of caffeine (Figure 4A) or rolipram
(Figure 4D). In the presence of caffeine, TGF-b1-induced
stimulation of transgelin promoter activity could be reduced in a
dose dependent manner (p,0.05) (Figure 4A). The same was also
true for rolipram (Figure 4D) (p,0.05). At 10 mM, caffeine was
able to completely antagonize TGF-b1-mediated transgelin
expression (p,0.05) (Figure 4A). When rolipram was used at
1 mM, TGF-b1-induced Smad activity was reduced by 64612%
(p,0.05) (Figure 4D). For analysis of mRNA and protein
expression, A549 cells were treated with TGF-b1 and with or
without caffeine or rolipram. Transgelin mRNA and protein
expression were measured 12 or 72 hours later, respectively.
Caffeine and rolipram diminished TGF-b1-mediated up-regula-
tion of transgelin mRNA by 6367% (p,0.05) (Figure 4B) and
9064% (p,0.05) (Figure 4E), respectively. The inhibitory effect of
caffeine and rolipram on TGF-b1 mediated up-regulation of
transgelin could also be detected on the protein level by Western
blot for caffeine in a dose dependent manner (Figure 4C) and for
rolipram (Figure 4F).
Altogether, these data confirmed that both caffeine and
rolipram are able to inhibit TGF-b1-mediated up-regulation of
transgelin on the promoter-, mRNA-, and protein-level in lung
epithelial cells.
Figure 3. TGF-b1 increases and caffeine decreases transgelin expression in lung epithelial cells. A549 cells were incubated with TGF-b1
(A–C) or caffeine (D–F) in indicated concentrations and for various timepoints. Transgelin promoter (A+C), real-time PCR (B+E) and Western blot (C+F)
analysis was performed. Means6SD of at least n = 3 independent experiments are shown. In C+F representative immunoblots of at least three
independent experiments are shown. * p,0.05 compared to control cells.
doi:10.1371/journal.pone.0097357.g003
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Transgelin silencing with shRNA in lung epithelial cells
To study the functional role of reduced transgelin expression in
lung epithelial cells, we generated lentiviral vectors mediating
expression of transgelin-specific shRNA. Transduction of A549
cells with those lentiviral vectors resulted in a significant decrease
of basal transgelin mRNA levels (Figure 5A) in comparison to
corresponding scrambled controls. The induction of transgelin
mRNA expression after TGF-b1 treatment described above was
also inhibited by the transgelin-specific shRNA (Figure 5A). A
TGF-b1-induced up-regulation of transgelin on the protein level
could also be prevented by transgelin-specific shRNA in compar-
ison to cells expressing non-specific scrambled shRNA (Figure 5B).
Figure 4. Caffeine and rolipram inhibit TGF-b1 induced transgelin expression in lung epithelial cells. A+D: The transgelin promoter
luciferase construct was transiently transfected into A549 cells. Cells were then treated with TGF-b1 (10 ng/ml) and/or different concentrations of
caffeine (A) or rolipram (D). Firefly luciferase activity was normalized to the activity of Renilla luciferase under control of the thymidine kinase
promoter. Relative luciferase activity compared to controls is shown. * p,0.05 compared to control cells,# p,0.05 compared to TGF-b1 treated cells.
B+C/E+F: A549 cells were incubated with TGF-b1 with or without different concentrations of caffeine or rolipram. Realtime PCR of transgelin mRNA
was performed after 12 h (B+E) and Western blot analysis after 72 h (C+F). Relative mRNA levels of transgelin were calculated by normalizing signals
to detected GAPDH mRNA (B+E) and compared to untreated cells. Means6SD of at least n = 3 independent experiments are shown. In C+F,
representative immunoblots for caffeine (C; triplicates) or rolipram (F; duplicates) against transgelin and b-actin are shown. * p,0.05 compared to
control cells, # p,0.05 compared to cells treated with TGF-b1.
doi:10.1371/journal.pone.0097357.g004
Effect of Caffeine and Rolipram on Airway Remodelling
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These results demonstrated that basal and TGF-b1-induced
production of transgelin in lung epithelial cells could be
significantly abolished by transgelin-specific shRNA.
Effect of transgelin gene silencing on Smad signalling in
lung epithelial cells
To study the possible effect of transgelin on Smad-signalling in
lung epithelial cells, the TGF-b1–sensitive (CAGA)12- and the
p3TP-luciferase construct were transfected into A549 cells in
which transgelin expression was knocked down by transgelin-
specific shRNA. After TGF-b1 treatment a reduction of TGF-b1-
induced luciferase activity to 40% (Figure 6A) or 16% (Figure 6B)
was observed in cells expressing transgelin-specific shRNA
compared with control cells (p,0.05). The inhibitory effect of
transgelin knockdown on TGF-b1 induced CTGF expression
could also be confirmed on the protein level by Western blot
(Figure 6C). To study the possible influence of transgelin on
Smad2/3 protein phosphorylation a western-blot against Smad2/
3-P was performed (Figure 6D). No difference in phosphorylation
of Smad2/3 could be found between cells with transgelin knock-
down and control cells.
Discussion
In this study, we describe inhibitory effects of caffeine and
rolipram on Smad signalling and the expression of TGF-b-
regulated genes involved in airway remodelling. Beyond their anti-
inflammatory effects, an understanding of these mechanisms might
help to explain protective effects of caffeine and rolipram in airway
remodelling processes during chronic lung diseases like BPD.
In the neonatal intensive care, methylxanthines including
caffeine and theophylline are widely used for the treatment of
apnea of prematurity and weaning from the ventilator [23].
Furthermore, reduction of the incidence of BPD in premature
infants has been attributed to the use of methylxanthines [23]. In
this context, also anti-inflammatory properties of caffeine have
been proposed [38–40]. Another recently described pharmaco-
logical common target for caffeine and glucocorticoids in the lung
is the surfactant system [35,41]. However, until now only a few
studies have assessed direct effects of caffeine and PDE-4 inhibitors
on molecular mechanisms involved in remodelling processes.
Theophylline suppressed TGF-b-induced type I collagen and
alpha smooth muscle actin (a-SMA) expression in lung fibroblasts
[42]. The anti-fibrotic effects of theophylline are at least partly
mediated through the cAMP-PKA pathway [42]. In addition,
caffeine and its metabolites suppressed TGF-b-dependent and -
independent CTGF expression in the liver via a mechanism that
involves reduction of the steady state concentration of total Smad2
protein, decreased phosphorylation of Smad3, and up-regulation
of the nuclear receptor peroxisome proliferator-activated receptor
(PPAR) c [43]. Caffeine was able to enforce proteasomal Smad2
degradation by enhancing the activity of Smurf2, a member of the
family of E3 ubiquitin ligases with the consequence that Smad2 is
increasingly bound to ubiquitin and proteasomally degraded [43].
Our results confirmed that caffeine can also down-regulate TGF-
b1 induced CTGF expression in lung epithelial cells. Beside
CTGF, transgelin could be identified as another new caffeine-
regulated gene involved in airway remodelling processes after lung
injury.
Transgelin, also called SM22a, was first described as a 22 kDa
protein of unknown function in smooth muscles [44]. Its
expression has been detected in several types of epithelial cells
[45] including the lung epithelial cells line A549 [18]. A549 cells
have been used in several other studies to analyze different aspects
of airway remodelling, especially in defining roles of PDE-4
inhibitors [46–48]. It is known that A549 cells express high levels
of PDE-4, lower levels of PDE-1 and PDE-3, and have a minor
PDE-5 activity [48]. Intracellular transgelin is localized in the
cytoskeleton apparatus and binds to actin filament bundles [49].
Upon tissue injuries, transgelin is increasingly expressed in lung
epithelial cells and may contribute to epithelial mesenchymal
transition (EMT) in lung fibrosis [18]. EMT, in which fully
differentiated lung epithelial cells change to fibroblasts and
myofibroblasts, plays an important role not only in lung
development but also in wound healing and lung fibrosis
[46,50]. TGF-b1 can induce transgelin expression and the
Smad3/4 complex is involved in the immediate response of the
transgelin promoter to TGF-b1 induction [13]. We confirmed the
formerly described TGF-b1-induced transgelin expression in lung
epithelial cells by Ye et al. [18]. As a new aspect, we showed that
basal expression and TGF-b1 induced up-regulation of transgelin
could be blocked by caffeine and rolipram.
Figure 5. Effect of transgelin-specific shRNA on basal and TGF-
b1 mediated induction of transgelin mRNA- and protein-
expression in lung epithelial cells. Transgelin was down-regulated
by transgelin-specific shRNA (right side; ‘‘transgelin shRNA’’) compared
with control cells, which were expressing non-specific shRNA (left side;
‘‘scrambled shRNA’’). A549 cells were then cultured in serum reduced
medium (0.2% FCS) for 24 h before treatment with TGF-b1. Total RNA
and protein was isolated after incubation with TGF-b1 in different
concentrations. Transgelin mRNA and protein levels were detected by
real time-PCR (after 24 h) (A) or by Western blot analysis (after 48 h) (B),
respectively. Means6SD of at least n = 3 independent experiments are
shown. In B, a representative immunoblot of at least three independent
experiments is shown. * p,0.05 compared to control cells, #,0.05
compared to ‘‘scrambled shRNA’’.
doi:10.1371/journal.pone.0097357.g005
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To analyze the function of transgelin in A549 cells, we modified
transgelin expression by transgelin mRNA knockdown using RNA
interference. We found that knockdown of transgelin using specific
shRNA reduced TGF-b1 induced Smad-signalling and CTGF
expression by more than 50%. Similar, Yu et al. described that
TGF-b induced migration of alveolar epithelial type II cells could
be reduced by transgelin knockdown [18]. It was hypothesized
before that there could be a possible association between the TGF-
b signalling pathway and the actin cytoskeleton, especially with
transgelin [22]. A possible connection between the proposed
reduction of transgelin expression and an impaired Smad
signalling could be confirmed in our experiments. Our results
demonstrated that transgelin expression can influence TGF-b
induced Smad-specific gene transactivation, which we have shown
in two different Smad dependent luciferase assay and by the
regulation of the TGF-b regulated gene CTGF. However, TGF-b
mediated Smad2/3 phosphorylation remained unaffected in
transgelin knock down cells. A possible explanation of this results
could be that the cytoskeleton protein transgelin could influence
nuclear translocation of the Smad2/3P complex in the nucleus,
DNA binding of the Smad2/3P complex, or the interaction of
Smad2/3P with transcriptional co-activators like CBP/p300.
Further studies are planned to investigate possible molecular
mechanisms involved in interactions between Smad molecules and
the cytoskeleton protein transgelin in more detail.
Since the here described effects of caffeine on Smad signalling
and CTGF/transgelin expression could only be found at high
caffeine but physiological rolipram concentrations, the effect of
caffeine on Smad signalling seemed to be mediated by an
inhibition of the PDE-4, leading to an increase of intracellular
cAMP. The cAMP pathway was described before as a possible
regulator of TGF-b-mediated effects [51,52]. Treatment of human
dermal fibroblasts with db-cAMP or forskolin, an established
artificial activator of adenylate cyclase and inducer of increased
cAMP levels, antagonized inductive effects of TGF-b on the
expression of the prototypical TGF-b-responsive genes collagen,
CTGF, tissue inhibitor of matrix metalloproteinase-1, and
plasminogen activator inhibitor type I (PAI-1)[52]. In our study
we could also mimic the effect of caffeine on Smad signalling by
rolipram and db-cAMP. In addition, Schiller et al. could show that
increased intracellular cAMP prevented TGF-b induced Smad-
specific gene transactivation, although TGF-b-mediated Smad
Figure 6. Effect of transgelin silencing on Smad signalling in lung epithelial cells. Transgelin was down-regulated by transgelin-specific
shRNA (right side;’’transgelin shRNA’’) and compared with control cells, which were expressing non-specific shRNA (left side; ‘‘control shRNA’’). A+B.
After down-regulation of transgelin by specific shRNA, the TGF-b1–sensitive (CAGA)12-luciferase construct (A) or the p3TP-luciferase construct (B)
were transiently transfected into A549 cells. Cells were then treated with or without TGF-b1 (10 ng/ml). Firefly luciferase activity was normalized to
the activity of Renilla luciferase under control of the thymidine kinase promoter. * p,0.05 compared to control cells,# p,0.05 compared to ‘‘control
shRNA’’. C. Cells were incubated with TGF-b1 (10 ng/ml) and 48 h later Western blot analysis of CTGF, transgelin, and b-actin was performed. A
representative immunoblot of at least three independent experiments is shown. D. Phosphorylation of endogenous Smad2/3 protein. A549 cells
were stimulated with TGF-b1 (10 ng/ml) for 10, 30, or 120 minutes. Smad2/3 phosphorylation was detected by immunoblotting with anti-phospho-
Smad2/3 antibodies. A representative immunoblot of 3 independent experiments is shown.
doi:10.1371/journal.pone.0097357.g006
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phosphorylation and nuclear translocation were not unaffected
[52]. However, increased cAMP levels are able to inhibit TGF-b
induced interaction of Smad3 with its transcriptional co-activator
cAMP-response element-binding protein (CREB)-binding protein
(CBP)/p300 [51,52]. These results suggest that suppression of
TGF-b/Smad signalling and resulting gene transactivation by
cAMP-inducing agents like caffeine or rolipram could occur via
PKA-dependent, CREB mediated disruption of the SMAD-CBP/
p300 complex [51,52].
A limitation of this study is that the effect of caffeine could only
be observed at high concentrations. In contrast, treatment of
premature infants with caffeine can result in serum concentrations
of 100-500 mM [53]. Although a concentration dependent effect of
caffeine on liver and lung tissue injury could be described being
more protective at higher concentrations and exacerbating at
lower concentrations [54,55], concentrations used in this study
had to be high (5–10 mM) to be effective and are thus
therapeutically impracticable. Therefore as a second pharmaco-
logical substance, the respective capacities of rolipram, a more
exclusive PDE4-inhibitor of the first generation, were investigated.
Our results showed that an inhibition of Smad-signalling and
reduction of CTGF/transgelin expression by caffeine, could also
be detected for rolipram. For the latter however, effective
concentrations were in a more physiological range and not toxic
in comparison to those of caffeine.
As described before by other groups, TGF-b1 is able to induce
Smad3 phosphorylation in A549 cells [46]. However, Smad3
phosphorylation could not be blocked by treatment with rolipram
at low concentrations (0.1–1 mM) as described in our study [46]. In
our test system, we also could not detect an effect of rolipram on
Smad signalling at these low concentrations. However, another
study showed that PDE-4 inhibitors are potent antagonists of
TGF-b signalling and therefore this is in accordance with our
results. Here, the second generation PDE-4 inhibitor roflumilast
antagonized the induction of CTGF, collagen I, and fibronectin by
TGF-b in human airway smooth muscle cells [56]. This effect was
different from other applied medications during treatment of
chronic lung diseases like corticosteroids or long-acting b2-agonists
because those drugs could not prevent the accumulation of TGF-
b–induced proteins in the lung [56]. Quite contrary, corticoste-
roids alone induced expression of CTGF, collagen I, and
fibronectin [56]. In addition, rolipram could inhibit epithelial-
mesenchymal transition (EMT) in a Smad independent manner in
A549 cells [46]. Another aspect is that PDE-4 inhibitors were also
effective in inhibiting the secretion of pro-matrix metalloprotei-
nases (pro-MMP-1 and pro-MMP-2) induced by TNF-a [57].
Tissue destruction, which occur secondary to airway remodelling
inflammation, has been linked to overexpression of matrix
metalloproteinases (MMPs). Our own group described an additive
effect of rolipram on steroid induced SP-B expression, which
might explain a possible protective effect of PDE-4 inhibitors on
lung homeostasis [35].
These in vitro observations and the here described inhibitory
effects of rolipram on Smad signalling and CTGF/transgelin
expression in lung epithelial cells underline that PDE-4 inhibitors
may offer a novel therapeutic strategy for respiratory diseases and
could possibly also provide a therapeutic option for very preterm
infants with BPD. The effect of different PDE-4 inhibitors (e.g.
rolipram, piclamilast, cilomilast) was also investigated in different
animal models in which BPD was induced by hyperoxia [27–31]
or chorioamnionitis [58]. In these studies, PDE-4 inhibitors either
protected against BPD or reversed the aberrant remodelling of the
alveolar architecture in response to injury. In addition, PDE-4
inhibition was shown to have anti-inflammatory properties, to
attenuate pulmonary fibrin deposition and vascular alveolar
leakage, and to prolong survival in hyperoxia-induced neonatal
lung injury [30]. These findings are also in agreement with
observations that PDE-4 inhibition reduced inflammatory re-
sponse in various other animal models of acute pulmonary
inflammation, including lipopolysaccharide (LPS) and antigen-
induced lung injury [59,60].
Conclusions
It is tempting to speculate that apart from anti-inflammatory
effects, caffeine and rolipram may directly antagonize aberrant
Smad signalling which in turn improves pathological changes in
alveolar architecture observed in BPD or other chronic inflam-
matory lung diseases. Selective PDE-4 inhibitors like rolipram may
have the potential to improve beneficial effects of theophylline and
caffeine thereby reducing adverse effects, although existing
inhibitors appear to be limited by similar problems [61]. To
overcome these pitfalls, administration of more subtype-selective
PDE-4 inhibitors by the inhalation route may be the ideal
approach to decrease those side effects and to similarly enhance
anti-inflammatory and protective properties on airway remodel-
ling processes [62,63]. In this context, topical administration of
PDE-4B selective inhibitors may probably have a superior
therapeutic ratio in the future [26,64].
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